Shares of TRIB stock opened at $1.28 on Thursday. Trinity Biotech has a 52-week low of $0.86 and a 52-week high of $3.98. The stock has a market cap of $26.75 million, a PE ratio of 14.22 and a beta of 1.33. The firm’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.41.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last announced its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.13). Trinity Biotech had a net margin of 0.94% and a negative return on equity of 27,745.46%.
About Trinity Biotech (Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.